Sustained-Release Ophthalmic Composition via Biodegradable Polymer Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for posterior eye diseases face challenges in maintaining effective dosing intervals and drug retention, leading to insufficient therapeutic effects due to inadequate drug delivery and retention in the eye.
Innovation Solution
A terpenoid derivative, produced through biotransformation using specific strains like Chaetomium globosum and Bacillus species, is formulated into a sustained-release pharmaceutical composition using biodegradable polymers like polylactic acid, allowing for prolonged pharmacological action and improved drug delivery to the vitreous body.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical compositions are used for posterior eye diseases, then the formulation is simple and easy to manufacture, but the drug retention in the eye is insufficient and therapeutic effects are inadequate
Solution Approach 1:
The patent uses a composite formulation consisting of terpenoid derivative (active ingredient) combined with biodegradable polymer matrix (sustained-release carrier). This composite structure enables both sustained drug delivery to maintain therapeutic levels in the eye and controlled release kinetics, resolving the contradiction between simple formulation and effective drug retention.
2Duration of action of moving object
If frequent administration is performed to maintain effective dosing intervals, then the therapeutic effect is maintained, but the burden of administration increases and patient compliance decreases
Solution Approach 1:
The sustained-release formulation provides continuous drug delivery to the eye over extended periods (weeks to months), eliminating the need for frequent administrations. The biodegradable polymer matrix continuously releases the terpenoid derivative at controlled rates, maintaining therapeutic effects without requiring repeated patient interventions.
3Reliability
If high concentration of active ingredient is used to ensure sufficient therapeutic effect, then the efficacy is improved, but the risk of side effects and toxicity increases
Solution Approach 1:
The formulation employs periodic/cyclic release patterns where the biodegradable polymer matrix gradually degrades and releases the terpenoid derivative in controlled pulses or sustained low concentrations over time. This prevents sudden high concentration spikes that cause toxicity while maintaining adequate therapeutic levels through continuous low-dose delivery.
4Duration of action of moving object
If sustained-release formulation is used to reduce administration frequency, then the duration of action is extended, but the formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent achieves sustained-release functionality by changing the physical-chemical parameters of the formulation system - specifically using biodegradable polymers with controlled molecular weight, composition, and degradation rates. These parameter adjustments enable extended drug release without requiring complex multi-component systems or sophisticated manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The terpenoid derivative exhibits excellent anti-inflammatory and cytoprotective actions, maintaining therapeutic effects for at least one week, reducing the frequency of administration and enhancing treatment efficacy for posterior eye diseases such as age-related macular degeneration and diabetic macular edema.
Implementation Method 1
the terpenoid derivative has the ability to activate the Keap1/Nrf2/ARE signaling pathway
Implementation Method 2
using biodegradable polymers like polylactic acid, allowing for prolonged pharmacological action
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body